TipRanks
Advertisement
Advertisement
Lakefront Biotherapeutics Steps Up Share Buybacks as Autoimmune Pipeline Advances
PremiumCompany AnnouncementsLakefront Biotherapeutics Steps Up Share Buybacks as Autoimmune Pipeline Advances
19d ago
Lakefront Biotherapeutics Expands Share Buyback Amid Strong Capital Position
Premium
Company Announcements
Lakefront Biotherapeutics Expands Share Buyback Amid Strong Capital Position
26d ago
Lakefront Biotherapeutics boosts buyback as it advances autoimmune pipeline
Premium
Company Announcements
Lakefront Biotherapeutics boosts buyback as it advances autoimmune pipeline
1M ago
Lakefront Biotherapeutics Expands Share Buyback, Bolstering Capital Strategy
PremiumCompany AnnouncementsLakefront Biotherapeutics Expands Share Buyback, Bolstering Capital Strategy
2M ago
Lakefront Biotherapeutics price target lowered to $26 from $30 at Morgan Stanley
Premium
The Fly
Lakefront Biotherapeutics price target lowered to $26 from $30 at Morgan Stanley
2M ago
Lakefront Biotherapeutics Boosts Immunology Push With Ouro Deal and Strong Cash Outlook
Premium
Company Announcements
Lakefront Biotherapeutics Boosts Immunology Push With Ouro Deal and Strong Cash Outlook
2M ago
Judah Frommer Maintains Hold on LKFT, Citing Early but Strategic Gamgertamig Acquisition and Limited Economic Upside
PremiumRatingsJudah Frommer Maintains Hold on LKFT, Citing Early but Strategic Gamgertamig Acquisition and Limited Economic Upside
3M ago
Lakefront Biotherapeutics announces EUR 50M share repurchase program
Premium
The Fly
Lakefront Biotherapeutics announces EUR 50M share repurchase program
4M ago
Premium
Company Announcements
Lakefront Biotherapeutics names Eric Hedrick Chief Medical Officer to steer post‑Ouro R&D push
4M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―